Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2021

The Pharma Closeout tracks 66 deals, $182.9B in disclosed deal value, 25 with a post-close Outcome Score for the year 2021.

Median Critic Score: 73  ·  Median Outcome Score: 58

Best outcome: Merck & Co. Inc. / Acceleron Pharma Inc. (90)  ·  Weakest outcome: Pfizer Inc. / Trillium Therapeutics Inc. (21)

All 66 deals

• Merck & Co. Inc. / Acceleron Pharma Inc. — 2021 · $11.5B · Worked — the deal delivered on its rationale.
• Amgen Inc. / Five Prime Therapeutics — 2021 · $1.9B · Worked — the deal delivered on its rationale.
• Thermo Fisher Scientific Inc. / PPD Inc. — 2021 · $17.4B · Worked — the deal delivered on its rationale.
• Pfizer Inc. / Arvinas, Inc. — 2021 · $2.4B · Worked — the deal delivered on its rationale.
• Jazz Pharmaceuticals PLC / GW Pharmaceuticals — 2021 · $7.2B · Worked — the deal delivered on its rationale.
• Sanofi SA / Amunix Pharmaceuticals Inc. — 2021 · $1.2B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / Ionis Pharmaceuticals, Inc. — 2021 · $4.2B · Largely worked — most objectives met.
• Horizon Therapeutics plc / Viela Bio Inc. — 2021 · $3.0B · Largely worked — most objectives met.
• Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. — 2021 · $3.3B · Largely worked — most objectives met.
• Pfizer Inc. / Arena Pharmaceuticals — 2021 · $6.7B · Largely worked — most objectives met.
• Sanofi SA / Kadmon Holdings Inc. — 2021 · $1.9B · Largely worked — most objectives met.
• Roche Holding AG / GenMark Diagnostics — 2021 · $1.8B · Largely worked — most objectives met.
• CSL Limited / Vifor Pharma Group — 2021 · $11.7B · Mixed — partial payoff, real shortfalls.
• ICON plc / PRA Health Sciences Inc. — 2021 · $12.0B · Mixed — partial payoff, real shortfalls.
• Sanofi SA / Kymab Ltd — 2021 · $1.4B · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / Pandion Therapeutics — 2021 · $1.9B · Mixed — partial payoff, real shortfalls.
• ProPhase Labs / Nebula Genomics — 2021 · $15M · Mixed — partial payoff, real shortfalls.
• Baxter International Inc. / Hillrom Holdings Inc. — 2021 · $12.4B · Mixed — partial payoff, real shortfalls.
• Bristol-Myers Squibb Company / Eisai Co., Ltd. — 2021 · $3.1B · Mixed — partial payoff, real shortfalls.
• Novartis AG / BeiGene Ltd. — 2021 · $2.2B · Underwhelmed — fell short of the thesis.
• Sanofi SA / Translate Bio Inc. — 2021 · $3.2B · Underwhelmed — fell short of the thesis.
• Agilent Technologies Inc. / Resolution Bioscience Inc. — 2021 · $695M · Underwhelmed — fell short of the thesis.
• GlaxoSmithKline plc / iTeos Therapeutics S.A. — 2021 · $2.1B · Did not work — the deal failed to deliver.
• Novartis AG / Gyroscope Therapeutics — 2021 · $1.5B · Did not work — the deal failed to deliver.
• Pfizer Inc. / Trillium Therapeutics Inc. — 2021 · $2.3B · Did not work — the deal failed to deliver.
• Thermo Fisher Scientific Inc. / Henogen S.A. (Novasep viral vector business) — 2021 · $875M
• Roivant Sciences Ltd. / Pfizer Inc. / Priovant Therapeutics — 2021 · $300M
• Boehringer Ingelheim International GmbH / Abexxa Biologics Inc. — 2021
• Eli Lilly and Company / Protomer Technologies — 2021 · $1.0B
• Amgen Inc. / Teneobio, Inc. — 2021 · $2.5B
• Eli Lilly and Company / Foghorn Therapeutics Inc. — 2021 · $1.7B
• Sumitomo Dainippon Pharma Co., Ltd. / Otsuka Pharmaceutical Co., Ltd. — 2021 · $270M
• Eli Lilly and Company / Kumquat Biosciences, Inc. — 2021 · $2.1B
• Sanofi SA / Origimm Biotechnology GmbH — 2021 · $170M
• Roche Holding AG (Genentech) / Adaptimmune Therapeutics plc — 2021 · $3.3B
• Catalent, Inc. / Bettera Holdings, LLC — 2021 · $1.0B
• Sanofi SA / Tidal Therapeutics, Inc. — 2021 · $470M
• Takeda Pharmaceutical Company Limited / Novavax Inc. — 2021 · $350M
• Organon & Co. / Forendo Pharma — 2021 · $954M
• Takeda Pharmaceutical Company Limited / GammaDelta Therapeutics Limited — 2021 · $350M
• AstraZeneca PLC (Alexion) / Caelum Biosciences — 2021 · $500M
• Eli Lilly and Company / Rigel Pharmaceuticals, Inc. — 2021 · $960M
• Novavax Inc. / SK Bioscience Co., Ltd. — 2021 · $300M
• Roche Holding AG / Shape Therapeutics Inc. — 2021 · $3.0B
• Sanofi SA / Owkin, Inc. — 2021 · $270M
• GlaxoSmithKline plc / Vir Biotechnology Inc. — 2021 · $345M
• Eli Lilly and Company / Asahi Kasei Pharma — 2021 · $230M
• Merck KGaA (EMD Serono) / Debiopharm — 2021 · $1.1B
• EQT Private Capital / Recipharm AB — 2021 · $2.8B
• BioNTech SE / Kite Pharma (Gilead Sciences) — 2021 · $250M
• Roche Holding AG (Genentech) / Recursion Pharmaceuticals, Inc. — 2021 · $12.0B
• AstraZeneca PLC / Ionis Pharmaceuticals, Inc. — 2021 · $3.6B
• AbbVie Inc. / Calico Life Sciences LLC — 2021 · $1.0B
• Illumina, Inc. / GRAIL, Inc. — 2021 · $7.1B
• Genmab A/S / Bolt Biotherapeutics, Inc. — 2021 · $880M
• Bayer AG / Vividion Therapeutics, Inc. — 2021 · $2.0B
• AbbVie Inc. / REGENXBIO Inc. — 2021 · $1.8B
• Amgen Inc. / Rodeo Therapeutics Corporation — 2021 · $721M
• GlaxoSmithKline plc / Alector, Inc. — 2021 · $2.2B
• Eli Lilly and Company / Merus N.V. — 2021 · $1.7B
• Perrigo Company Plc / HRA Pharma — 2021 · $2.1B
• Ipsen S.A. / GENFIT — 2021 · $543M
• Bristol-Myers Squibb Company / Agenus Inc. — 2021 · $1.6B
• MorphoSys AG / Constellation Pharmaceuticals, Inc. — 2021 · $1.7B
• Bristol-Myers Squibb Company / Immatics N.V. — 2021 · $920M
• Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG — 2021 · $1.1B

← Deal Library  ·  Interactive search  ·  How we score deals